APVO Aptevo Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: APVO
Price (delayed)
$1.43
Market cap
$4.7M
P/E Ratio
0
Dividend/share
N/A
EPS
$1,508.4
Enterprise value
-$499,277
Relative Growth:
Rel. Growth:
27
Relative Strength:
Rel. Strength:
0
Relative Valuation:
Rel. Valuation:
80
Relative Profitability:
Rel. Profitability:
4
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603,
Highlights
APVO's EPS has surged by 105% year-on-year
Aptevo Therapeutics's equity has increased by 46% YoY
Key stats
What are the main financial stats of APVO
Market
Valuations
Earnings
Shares outstanding
3.29M
Market cap
$4.7M
Enterprise value
-$499,277
Price to earnings (P/E)
0
Price to book (P/B)
0.09
Price to sales (P/S)
N/A
PEG
0
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$24.3M
Net income
-$24.03M
EBIT
-$24.03M
EBITDA
-$23.76M
Free cash flow
-$24.65M
Per share
Balance sheet
Liquidity
EPS
$1,508.4
EPS diluted
$1,508.4
Free cash flow per share
-$33.39
Book value per share
$16.09
Revenue per share
$0
TBVPS
$21.17
Total assets
$15.62M
Total liabilities
$9.1M
Debt
$4.21M
Equity
$6.52M
Working capital
$6.19M
Debt to equity
0.65
Current ratio
2.27
Quick ratio
1.92
Net debt/EBITDA
0.22
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-175.7%
Return on equity
-675.5%
Return on invested capital
-428.9%
Return on capital employed
-223.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APVO stock price
How has the Aptevo Therapeutics stock price performed over time
Intraday
0%
1 week
2.14%
1 month
1.42%
1 year
-99.25%
YTD
-98.34%
QTD
-1.38%
Financial performance
How have Aptevo Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$24.3M
Net income
-$24.03M
Gross margin
N/A
Net margin
N/A
The company's operating income rose by 6% YoY
APVO's net income is up by 3.7% YoY
Price vs fundamentals
How does APVO's price correlate with its fundamentals
Growth
What is Aptevo Therapeutics's growth rate over time
Valuation
What is Aptevo Therapeutics stock price valuation
P/E
0
P/B
0.09
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
APVO's EPS has surged by 105% year-on-year
APVO's P/B is 98% below its 5-year quarterly average of 4.5
Aptevo Therapeutics's equity has increased by 46% YoY
Efficiency
How efficient is Aptevo Therapeutics business performance
The return on equity has dropped by 154% year-on-year but it is up by 13% since the previous quarter
Aptevo Therapeutics's ROA has decreased by 49% YoY
The company's return on invested capital fell by 10% YoY and by 6% QoQ
Dividends
What is APVO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APVO.
Financial health
How did Aptevo Therapeutics financials performed over time
APVO's total assets is 72% higher than its total liabilities
APVO's total assets has soared by 87% QoQ and by 4.7% YoY
The quick ratio has grown by 29% YoY
The company's debt is 35% lower than its equity
The debt to equity has soared by 122% QoQ but it fell by 42% YoY
Aptevo Therapeutics's equity has increased by 46% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.